|Bid||12.15 x 3000|
|Ask||13.44 x 800|
|Day's Range||12.32 - 12.57|
|52 Week Range||8.27 - 16.27|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It hasn't been the best quarter for Amicus Therapeutics, Inc. (NASDAQ:FOLD) shareholders, since the share price has...
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]
The company reportedly considered other cities for a new facility, but the Orlando City Council approved a nearly $380,000 incentive deal Aug. 20 to attract it to Central Florida.
As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...
The expanded collaboration and licensing deal will include Amicus providing $50 million in research funding, over five years, to Penn's gene therapy program.
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Vision for fiscal 2023In its investor presentation, Amicus Therapeutics (FOLD) has guided for revenues of around $200 million and $300 million for its AT-GAA Novel ERT
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Performance in the first quarterIn the first quarter, Amicus Therapeutics (FOLD) reported 150 net new patients using Galafold therapy, meaning the total number of patients
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Amicus Therapeutics (FOLD) reported non-GAAP EPS of -$0.39, a YoY fall of 39.29% and lower than the consensus estimate by
Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Revenue guidanceIn its investor presentation, Amicus Therapeutics (FOLD) has guided for the revenues of its lead asset, Galafold, to fall in the range of $160 million to $180
Amicus or Portola: Which Is the Best Bet in May?Stock price movementsOn May 21, Amicus Therapeutics (FOLD) closed at $12.31, 3.97% higher than the previous close, 48.85% higher than the 52-week low of $8.27, and 30.14% lower than the 52-week high of
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cranbury, New Jersey-based company said it had a loss of 56 cents per share. Losses, adjusted for non-recurring costs, came to 39 cents per share. The results fell short of Wall Street expectations. ...
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.